# Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Participants

> **NCT00284986** · PHASE2 · COMPLETED · sponsor: **Mesoblast, Inc.** · enrollment: 11 (actual)

## Conditions studied

- Graft Versus Host Disease

## Interventions

- **DRUG:** Prochymal

## Key facts

- **NCT ID:** NCT00284986
- **Lead sponsor:** Mesoblast, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11-18
- **Primary completion:** 2006-04-25
- **Final completion:** 2007-02-08
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00284986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00284986, "Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Participants". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00284986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*